Chin Med J (Engl). 2012 Sep;125(18):3207-10.
Xu Y, Zhang Y, Liu CY, Peng B, Wang JM, Zhang XJ, Li HF, Cui LY.
Source
Department of Neurology, Peking Union Medical College Hospital, Beijing, China.
Abstract
BACKGROUND:
Whether antibody to myelin oligodendrocyte glycoprotein (MOG) can be a diagnostic marker for multiple sclerosis (MS) is still controversial. Recent studies suggested that serum specific anti-MOG epitope antibody might be an MS specific marker. However, these studies did not include neuromyelitis optica (NMO) which might be proven to also have anti-MOG antibody. Hence, the present study was undertaken to investigate the clinical value of serum antibodies to 25 MOG epitopes in conventional MS (CMS) and NMO.
METHODS:
Serum anti-MOG epitope IgG was detected in 61 CMS patients, 54 NMO patients, and 77 healthy controls, using enzyme-linked immunosorbent assay (ELISA).
RESULTS:
Anti-MOG(27-38) IgG levels in both CMS and NMO patients were significantly higher than that in healthy controls (optical density (OD): 0.64 ± 0.38, 0.48 ± 0.23 vs. 0.19 ± 0.09; P = 0.000). CMS and NMO patients in relapse stage had significantly higher anti-MOG(27-38) IgG level than patients in remission stage (OD: 0.55 ± 0.14 vs. 0.24 ± 0.09, P = 0.027).
CONCLUSION:
Although serum anti-MOG epitope IgG could not differentiate MS from NMO, it may be a useful marker for monitoring disease activity.
PMID: 22964310 [PubMed – in process]
Link: http://www.cmj.org/Periodical/paperlist.asp?id=LW2012917340010606621&linkintype=pubmed